Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.

Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...

AstraZeneca (NASDAQ:AZN) said its drug Tagrisso has been approved by EU regulators for the treatment of EGFR-mutation ...

AstraZeneca AZN announced that its blockbuster cancer drug, Tagrisso (osimertinib), has been approved in the EU for expanded ...

台湾胸腔暨重症加护医学会理事长陈育民表示，常见的非小细胞肺癌中，约55％为EGFR突变型，其中Exon 19和Exon 21为最常见的基因突变，合计占85 ...

AstraZeneca’s Tagrisso (osimertinib) has been approved by the European Commission (EC) to treat a new subset of lung cancer ...

At ASCO, the stellar PFS data sparked speculation that Tagrisso will become the standard of care in this type of early lung ...

Belgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has ...

Cilag’s Rybrevant in combo with Lazcluze for first-line treatment of patients with EGFR-mutated advanced NSCLC: Beerse, Belgium Tuesday, Dec ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, discussed the mechanism of action of amivantamab and the ...

In August, the FDA approved Rybrevant in combination with oral EGFR-TKI inhibitor ... metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations. The FDA approval was ...